Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KAT6A | Q92794 | 6/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.43 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | CA7 | P43166 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | NQO1 | P15559 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.41 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24429673 | 0.87 | KAT6A (0.45) | KAT6ATSHRCA12CA1CA2 | |
| SCHEMBL29651880 | 0.83 | CA1 (0.54) | KAT6ATSHRCA12CA1CA2 | |
| SCHEMBL34468880 | 0.81 | TSHR (0.58) | TSHRTRPV4ALDH1A1KDM4EHTT | |
| SCHEMBL14775287 | 0.81 | SMN1; SMN2 (0.48) | KAT6ATRPV4ALDH1A1NPSR1 | |
| SCHEMBL29595784 | 0.81 | SMN1; SMN2 (0.48) | KAT6ATRPV4ALDH1A1NPSR1 | |
| SCHEMBL26567164 | 0.81 | KAT6A (0.54) | KAT6ATSHRALDH1A1HTTLMNA | |
| SCHEMBL24429429 | 0.78 | KAT6A (0.52) | KAT6AALDH1A1FFAR1FFAR4 | |
| SCHEMBL9659543 | 0.78 | PDIA6 (0.53) | TSHRTRPV4CA12CA1CA2 | |
| SCHEMBL12082958 | 0.78 | TRPV4 (0.48) | TSHRTRPV4CA12CA1CA2 | |
| SCHEMBL10815132 | 0.76 | TRPV4 (0.54) | TSHRTRPV4CA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113795254-B | Pyrazolopyridine compounds for IRE1 inhibition | 奥普提卡拉公司 | 2024-08-09 | — | — | CN | disclosed |
| US-20230331719-A1 | Pyrazolopyridine Compounds and Methods of Inhibiting IRE1 Using Same | OPTIKIRA LLC (US) | 2023-10-19 | — | — | US | disclosed |
| US-20230331719-A1 | Pyrazolopyridine Compounds and Methods of Inhibiting IRE1 Using Same | OPTIKIRA LLC (US) | 2023-10-19 | — | — | US | disclosed |
| US-20230331719-A1 | Pyrazolopyridine Compounds and Methods of Inhibiting IRE1 Using Same | OPTIKIRA LLC (US) | 2023-10-19 | — | — | US | disclosed |
| US-20220153734-A1 | Pyrazolopyridine Compounds For IRE1 Inhibition | Optikira, LLC | 2022-05-19 | — | — | US | disclosed |
| CN-113795254-A | Pyrazolopyridine compounds for IRE1 inhibition | 奥普提卡拉公司 | 2021-12-14 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230331719-A1 | Pyrazolopyridine Compounds and Methods of Inhibiting IRE1 Using Same | XBP1, ERN1, ERN2 | KAT6A 4736/4885TSHR 4302/4885TRPV4 2071/4885 |
| US-20220153734-A1 | Pyrazolopyridine Compounds For IRE1 Inhibition | XBP1, ERN1, ERN2 | KAT6A 4658/4885TSHR 4069/4885TRPV4 2125/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.